NY Times
JANUARY 22, 2021
After the surprise discovery of an extra dose in every vial, Pfizer executives successfully lobbied the F.D.A. to change the vaccine’s formal authorization language. The company charges by the dose.
pharmaphorum
JANUARY 22, 2021
Gilead Sciences says its antiviral Veklury should be effective against the new, more contagious COVID-19 variants discovered in the UK and South Africa. According to the US biopharma company, genetic analyses of publicly available sequences for the new variants of SARS-CoV-2 suggest the mutations in the viral spike protein that have made them more transmissible shouldn’t affect the way Veklury (remdesivir) works.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharma Times
JANUARY 18, 2021
Therapy approved for the treatment of paediatric patients with anaplastic large cell lymphoma
Outsourcing Pharma
JANUARY 18, 2021
A representative from the global CRO outlines how forces like COVID-19, decentralized studies, globalization and others are driving change in the industry.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
NY Times
JANUARY 22, 2021
After the surprise discovery of an extra dose in every vial, Pfizer executives successfully lobbied the F.D.A. to change the vaccine’s formal authorization language. The company charges by the dose.
pharmaphorum
JANUARY 18, 2021
Public health authorities in California are seeking a halt on dosing of one lot of Moderna’s COVID-19 vaccine after reports of allergic reactions at one immunisation clinic. According to state epidemiologist Dr Erica Pan, there were a higher-than-expected number of suspected allergic reactions at a community clinic being used to administer the shot, with some people needing medical attention in a 24-hour period.
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
Outsourcing Pharma
JANUARY 18, 2021
A leader from Oracle Health Sciences examines the dynamic, challenging year and highlights creativity and ingenuity displayed by research professionals.
NY Times
JANUARY 21, 2021
A monoclonal antibody protected residents and staff members in facilities where the virus had appeared.
pharmaphorum
JANUARY 19, 2021
A survey by rare disease patient network Raremark found that 86% of the community members asked were interested in taking part in clinical trials. CEO Jeremy Edwards looks at how decentralised trial models can solve some of the challenges for clinical trial recruitment in rare disease. With low and geographically dispersed patient populations in rare disease, deciding where best to place trial sites can be a headache for sponsors.
Pharma Times
JANUARY 20, 2021
UK biotech company will collaborate with Lawrence Livermore National Laboratory
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Outsourcing Pharma
JANUARY 21, 2021
The trials, funded by the American Heart Association, will harness the companyâs Verisense wearable sensor platform to examine brain-heart health links.
NY Times
JANUARY 21, 2021
A monoclonal antibody protected residents and staff members in facilities where the virus had appeared.
pharmaphorum
JANUARY 21, 2021
A partnership between University of Oxford, the Earlham Institute, and the global pharmaceutical companies Biogen Inc and Boehringer Ingelheim is announced today to investigate a new drug target for the treatment of schizophrenia. This is the first project to be funded by the international Psychiatry Consortium, a £4 million collaboration between seven global pharmaceutical companies, and two leading research charities, convened and managed by the Medicines Discovery Catapult, that supports high
Pharma Times
JANUARY 22, 2021
Company has completed genetic analysis for UK and South African variants
Outsourcing Pharma
JANUARY 19, 2021
The pharma giant has invested in the clinical trial exploring the viability of Vedanta Biosciencesâ VE202 inflammatory bowel disease treatment candidate.
NY Times
JANUARY 21, 2021
A combination of two injectable drugs will provide an alternative to daily pills for people with H.I.V.
pharmaphorum
JANUARY 18, 2021
AstraZeneca and Daiichi Sankyo’s Enhertu cancer drug has picked up a second indication, in patients who have stomach cancer and haven’t responded to Roche’s Herceptin (trastuzumab). This latest indication adds to Enhertu first approval at the end of 2019 for advanced HER2-positive breast cancer after two or more HER2-targeted regimens. Around one in five gastric cancers are HER2-positive, opening up a new market niche for AstraZeneca and Daiichi Sankyo, who have been working on Enhertu (trastuzu
Pharma Times
JANUARY 20, 2021
Approximately one in five breast cancer cases in the EU are HER2-positive
Drug Patent Watch
JANUARY 22, 2021
Annual Drug Patent Expirations for INLYTA Inlyta is a drug marketed by Pf Prism Cv and is included in one NDA. It is available from two suppliers. There are four…. The post New patent for Pf Prism drug INLYTA appeared first on DrugPatentWatch - Make Better Decisions.
NY Times
JANUARY 18, 2021
Gov. Andrew M. Cuomo of New York said on Monday that he had asked the pharmaceutical giant Pfizer to directly sell doses to the state, so that it does not have to depend solely on the federal government to distribute doses.
pharmaphorum
JANUARY 20, 2021
Laboratory studies have confirmed that antibodies stimulated by Pfizer and BioNTech’s COVID-19 vaccine can neutralise the new, more transmissible variant of SARS-CoV-2 identified in the UK. The results of the study – published online prior to peer review – are among the first data to indicate that any of the approved coronavirus vaccines can effectively target the mutated spike protein in the UK strain, known as B.1.1.7 lineage or VOC 202012/01.
Pharma Times
JANUARY 22, 2021
Cost-effectiveness estimates 'uncertain', according to NICE
Drug Patent Watch
JANUARY 22, 2021
Annual Drug Patent Expirations for CERDELGA Cerdelga is a drug marketed by Genzyme Corp and is included in one NDA. It is available from one supplier. There are four patents…. The post New patent for Genzyme Corp drug CERDELGA appeared first on DrugPatentWatch - Make Better Decisions.
NY Times
JANUARY 22, 2021
Seeking to secure vital supplies, the authorities in the country maneuvered around anticorruption rules that require public disclosure of contracts.
pharmaphorum
JANUARY 22, 2021
NICE has said that the NHS should not fund Bristol-Myers Squibb’s multiple sclerosis pill Zeposia (ozanimod) for relapsing multiple sclerosis in first draft guidance. The cost-effectiveness body said that trial evidence showed Zeposia cuts the number of relapses and brain lesions compared with Biogen’s Avonex (interferon beta-1a). But in its first draft guidance NICE said that Zeposia’s effect on progression of disability is unclear.
Pharma Times
JANUARY 18, 2021
Partnership aims to transform HIV patient care with digital services
Drug Patent Watch
JANUARY 22, 2021
Annual Drug Patent Expirations for PHEXXI Phexxi is a drug marketed by Evofem Inc and is included in one NDA. It is available from one supplier. The generic ingredient in…. The post New patent for Evofem Inc drug PHEXXI appeared first on DrugPatentWatch - Make Better Decisions.
Drug Channels
JANUARY 22, 2021
Today’s guest post comes from Jason Coles, Senior Product Manager for Clinical Effectiveness at Wolters Kluwer, Health. Jason discusses the benefits of accessing patient information across clinical contexts. He introduces us to the Wolters Kluwer drug data solutions. These solutions promote interoperability and help healthcare businesses meet regulations related to health information exchange.
pharmaphorum
JANUARY 18, 2021
Johnson & Johnson’s Darzalex Faspro has become the first product approved by the FDA to treat light chain (AL) amyloidosis, a rare and often fatal blood cell disorder. The new indication is the second for Darzalex Faspro, a subcutaneous version of blockbuster intravenous therapy Darzalex (daratumumab) which is used to treat multiple myeloma on its own and as part of multiple combination therapies.
Pharma Times
JANUARY 19, 2021
Darzalex, Rozlytrek and Tavlesse among newly accepted drugs
Drug Patent Watch
JANUARY 22, 2021
Annual Drug Patent Expirations for INLYTA Inlyta is a drug marketed by Pf Prism Cv and is included in one NDA. It is available from two suppliers. There are four…. The post New patent for Pf Prism drug INLYTA appeared first on DrugPatentWatch - Make Better Decisions.
Pharma in Brief
JANUARY 20, 2021
On January 18, 2021, the Federal Court ( FC ) issued its latest COVID-19 Practice Direction , which supersedes all its prior COVID-19 practice directions. The FC’s facilities in Ontario and Quebec have been closed in light of the recent public health measures to combat the pandemic. The FC will continue its operations remotely in these two provinces until further notice.
pharmaphorum
JANUARY 20, 2021
Ella Balasa says she owes her life to the experimental phage therapy she was able access in no small part thanks to her scientific background. Her mission, she told pharmaphorum, is to ensure everyone has the knowledge and power they need to navigate their own healthcare journey, no matter where they are from or what they do. Ella, 28, was diagnosed with cystic fibrosis – a rare genetic disease which causes a build-up of thick, sticky mucus in the lungs, digestive tract, and sinuses – at 18 mont
Pharma Times
JANUARY 21, 2021
Over 400,000 people in the UK live with RA
Drug Patent Watch
JANUARY 22, 2021
Annual Drug Patent Expirations for CERDELGA Cerdelga is a drug marketed by Genzyme Corp and is included in one NDA. It is available from one supplier. There are four patents…. The post New patent for Genzyme Corp drug CERDELGA appeared first on DrugPatentWatch - Make Better Decisions.
Expert insights. Personalized for you.
144 
Let's personalize your content